Abortion Safety and Use with Normally Prescribed Mifepristone in Canada
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the United States, mifepristone is available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, despite an absence of evidence to support such restrictions. Mifepristone has been available in Canada with a normal prescription since November 2017. METHODS: Using population-based administrative data from Ontario, Canada, we examined abortion use, safety, and effectiveness using an interrupted time-series analysis comparing trends in incidence before mifepristone was available (January 2012 through December 2016) with trends after its availability without restrictions (November 7, 2017, through March 15, 2020). RESULTS: A total of 195,183 abortions were performed before mifepristone was available and 84,032 after its availability without restrictions. After the availability of mifepristone with a normal prescription, the abortion rate continued to decline, although more slowly than was expected on the basis of trends before mifepristone had been available (adjusted risk difference in time-series analysis, 1.2 per 1000 female residents between 15 and 49 years of age; 95% confidence interval [CI], 1.1 to 1.4), whereas the percentage of abortions provided as medical procedures increased from 2.2% to 31.4% (adjusted risk difference, 28.8 percentage points; 95% CI, 28.0 to 29.7). There were no material changes between the period before mifepristone was available and the nonrestricted period in the incidence of severe adverse events (0.03% vs. 0.04%; adjusted risk difference, 0.01 percentage points; 95% CI, -0.06 to 0.03), complications (0.74% vs. 0.69%; adjusted risk difference, 0.06 percentage points; 95% CI, -0.07 to 0.18), or ectopic pregnancy detected after abortion (0.15% vs. 0.22%; adjusted risk difference, -0.03 percentage points; 95% CI, -0.19 to 0.09). There was a small increase in ongoing intrauterine pregnancy continuing to delivery (adjusted risk difference, 0.08 percentage points; 95% CI, 0.04 to 0.10). CONCLUSIONS: After mifepristone became available as a normal prescription, the abortion rate remained relatively stable, the proportion of abortions provided by medication increased rapidly, and adverse events and complications remained stable, as compared with the period when mifepristone was unavailable. (Funded by the Canadian Institutes of Health Research and the Women's Health Research Institute.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Segmented regression analysis of interrupted time series studies in medication use research
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00430.x · Cited by 3,279
Interrupted time series regression for the evaluation of public health interventions: a tutorial
Lopez Bernal, J., Cummins, S., & Gasparrini, A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw098 · Cited by 3,049
Haukoos, J. S., & Lewis, R. J. (2005) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2005.tb01958.x · Cited by 540
A systematic review to calculate background miscarriage rates using life table analysis
Ammon Avalos, L., Galindo, C., & Li, D. (2012) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.23014 · Cited by 329
Medical methods for first trimester abortion
Kulier, R., Kapp, N., Gülmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002855.pub4 · Cited by 284
Time Series Analysis Using Autoregressive Integrated Moving Average (ARIMA) Models
Nelson, B. K. (1998) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1998.tb02493.x · Cited by 262
Aiken, A., Lohr, P., Lord, J., Ghosh, N., & Starling, J. (2021) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16668 · Cited by 256
Hategeka, C., Ruton, H., Karamouzian, M., Lynd, L. D., & Law, M. R. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2020-003567 · Cited by 237
Self-citationA United Nations High Commissioner for Human Rights
Clark, R. S. (1972) · Springer eBooks · doi:10.1007/978-94-011-8800-5 · Cited by 209
Medication Abortion Up to 70 Days of Gestation
Society of Family Planning (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004082 · Cited by 158
Research works printed but not linked: 1
- 10.1197/j.aem.2004.11.018 · doi:10.1197/j.aem.2004.11.018 · Paper page
Cited by
Baraitser, P., Free, C., Norman, W. V., Lewandowska, M., Meiksin, R., Palmer, M. J., Scott, R. H., French, R., Wellings, K., Ivory, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066650 · Cited by 41
Self-citationCarson, A., Stirling-Cameron, E., Paynter, M. J., Norman, W. V., Munro, S. B., & Martin‐Misener, R. (2022) · Journal of Advanced Nursing · doi:10.1111/jan.15487 · Cited by 24
Self-citationTelemedicine for First-Trimester Medical Abortion in Canada: Results of a 2019 Survey
Renner, R., Ennis, M., Kyeremeh, A., Norman, W. V., Dunn, S., Pymar, H. C., & Guilbert, É. (2022) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2022.0245 · Cited by 18
Self-citationExperience of stigma and harassment among respondents to the 2019 Canadian abortion provider survey
Ennis, M., Renner, R., Olure, B., Norman, W. V., Begun, S., Martin, L. A., Harris, L. H., Kean, L., Seewald, M., & Munro, S. B. (2023) · Contraception · doi:10.1016/j.contraception.2023.110083 · Cited by 18
Self-citationAbortion services and providers in Canada in 2019: results of a national survey
Renner, R. M., Ennis, M., Contandriopoulos, D., Guilbert, E., Dunn, S., Kaczorowski, J., Darling, E. K., Albert, A., Styffe, C., & Norman, W. V. (2022) · CMAJ Open · doi:10.9778/cmajo.20210232 · Cited by 16
“Other evidence describing growth in the abortion work-force is emerging; 22,24,38–42 this growth appears to be associated with the 2017 introduction of mifepristone in Canada and the subsequent removal of restrictive regulations.”
Self-citation
Metadata
- Authors
- Schummers, L., Darling, E. K., Dunn, S., McGrail, K., Gayowsky, A., Law, M. R., Laba, T.-L., Kaczorowski, J., & Norman, W. V.
- Affiliations
- University of British Columbia (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-01-06
- Volume
- 386
- Issue
- 1
- Pages
- 57-67
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4200143757
- Cited by
- 71
- References
- 31
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 9 · 2023: 19 · 2022: 12
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- Institute of Health Services and Policy Research (Canada Chair in Prevention and Control of Hyperten, Early Career Researcher: ECI-167971, Health System Impact Fellowship 2018 Schummers, Patient-Oriented Research Award – Transition to, Project Grant PJT-168964 2020-24, Public Health Research Chair: CPP-329455-107837 20)
- British Columbia Ministry of Health (18183)
- Michael Smith Foundation for Health Research (17934, 2012-5139 HSR)
- Canada Research Chairs (Canada Research Chair in Access to Medicines)
- National Health and Medical Research Council (Early Career Fellowship (APP1110230))
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- mifepristone, abortion pills, abortion safety, risk evaluation and mitigation strategy, drug regulation, prescribing restrictions, misoprostol, Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abortion Safety and Use with Normally Prescribed Mifepristone in Canada. https://app.cochat.ai/papers/10.1056/nejmsa2109779
- The paper
- Schummers, L., Darling, E. K., Dunn, S., McGrail, K., Gayowsky, A., Law, M. R., Laba, T.-L., Kaczorowski, J., & Norman, W. V. (2022). Abortion Safety and Use with Normally Prescribed Mifepristone in Canada. New England Journal of Medicine. https://doi.org/10.1056/nejmsa2109779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.